0001582249 false 0001582249 2022-05-13 2022-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): May 13, 2022

 

RASNA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   333-191083   39-2080103

(State or other jurisdiction

of incorporation)

   (Commission File Number)   (IRS Employer
Identification No.)

 

 

420 Lexington Avenue, Suite 2525, New York, NY

   10170
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 646-396-4087

 

 

 

(Former name or former address, if changed since last report)

 

Copies to:

Jeffrey Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Telephone: (212) 653-8700

Facsimile: (212) 653-8701

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

 

 

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

On May 13-16, 2022, certain holders of Rasna Therapeutics, Inc.’s (the “Company”) convertible notes converted an aggregate $828,500 principal amount plus accrued interest into an aggregate 107,633,650 shares of the Company’s common stock.

 

-1-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 19, 2022

 

  RASNA THERAPEUTICS, INC.
     
  By:  /s/ Keeren Shah
    Name:  Keeren Shah
    Title: Chief Financial Officer

 

 

-2-

 

Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Actavia Life Sciences (CE) Charts.
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Actavia Life Sciences (CE) Charts.